A Director at Arrowhead Pharmaceuticals (ARWR) is Selling Shares


Yesterday, a Director at Arrowhead Pharmaceuticals (ARWR), Mauro Ferrari, sold shares of ARWR for $480K.

Following Mauro Ferrari’s last ARWR Sell transaction on June 28, 2019, the stock climbed by 19.9%.

See today’s analyst top recommended stocks >>

The company has a one-year high of $73.72 and a one-year low of $19.51. Currently, Arrowhead Pharmaceuticals has an average volume of 645.25K. The Company has a Price to Book ratio of 9.55.

Based on 6 analyst ratings, the analyst consensus is Strong Buy with an average price target of $72.50, reflecting a -36.3% downside.

Mauro Ferrari’s trades have generated a -45.9% average return based on past transactions. DailyInsider proprietary algorithm detects trades by the most influential insiders and selects attractive trading opportunities daily. To subscribe to the DailyInsider visit this page.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Arrowhead Pharmaceuticals, Inc. operates as a biopharmaceutical company. It develops medicines that treat intractable diseases by silencing the genes that cause them. The company was founded by R. Bruce Stewart in 1989 and is headquartered in Pasadena, CA.

Stay Ahead of Everyone Else

Get The Latest Stock News Alerts